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Abstract
The biological pathways involved in amyotrophic lateral sclerosis (ALS) remain elusive and
diagnostic decision-making can be challenging. Gene expression studies are valuable
in overcoming such challenges since they can shed light on differentially regulated path-
ways and may ultimately identify valuable biomarkers. This two-stage transcriptome-wide
study, including 397 ALS patients and 645 control subjects, identified 2,943 differentially
expressed transcripts predominantly involved in RNA binding and intracellular transport.
When batch effects between the two stages were overcome, three different models (support
vector machines, nearest shrunken centroids, and LASSO) discriminated ALS patients
from control subjects in the validation stage with high accuracy. The models’ accuracy
reduced considerably when discriminating ALS from diseases that mimic ALS clinically (N =
75), nor could it predict survival. We here show that whole blood transcriptome profiles are
able to reveal biological processes involved in ALS. Also, this study shows that using these
profiles to differentiate between ALS and mimic syndromes will be challenging, even when
taking batch effects in transcriptome data into account.
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease affecting motor
neurons in the brain and spinal cord. Except for riluzole, there is no disease-modifying treat-
ment and patients suffer from progressive paralysis that results in respiratory insufficiency
within three to five years [1,2]. Twin studies estimate the heritability of ALS to be 0.61 (95%
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confidence interval = 0.38–0.78), indicating that genetic risk factors play an important role in
ALS pathogenesis [3].
During the past years, a rapidly increasing number of genetic risk factors has been identi-
fied [4]. Based on these observations, multiple biological pathways have been linked to ALS
including RNA processing, oxidative stress, mitochondrial dysfunction, excitoxicity, axonal
transport and neuroinflammation [5,6]. Nevertheless, our understanding of ALS pathogenesis
remains incomplete.
Furthermore, important questions in clinical practice still have to be answered. Diagnostic
tests to confirm ALS are lacking: exclusion of alternative diagnoses remains essential but
causes considerable diagnostic delay [2,7]. Previous studies, including sophisticated neuroim-
aging techniques, proteomic analyses in plasma and CSF, or gene expression profiling, have
looked for diagnostic biomarkers, but challenges remain [8–13]. Observed patterns in bio-
marker research clearly require their predictive value to be assessed in well-defined patient
cohorts, preferably including disease mimics, which are encountered in referral clinics.
Gene expression studies may satisfy both needs since they can shed light on differentially
regulated pathways and identify valuable biomarkers [14,15]. Furthermore, whole blood gene
expression profiles are easily obtained and thereby facilitate studies including a large number
of cases and controls to improve the chance of finding a robust biomarker.
For these reasons, we used whole blood gene expression profiles in two large independent
cohorts of ALS patients, healthy controls and ALS-mimics and show that these profiles reflect
ALS pathophysiology. Using four different models we could reliably discriminate between
ALS patients and controls. The road to a true diagnostic biomarker, however, proved challeng-
ing considering the marked batch effects and reduced accuracy when discriminating between
ALS patients and ALS-mimics.
Methods and material
Patient selection
Patients were recruited from the out-patient clinic specialized in motor neuron diseases at the
University Medical Center Utrecht, The Netherlands. ALS patients fulfilled the revised El
Escorial criteria for possible, probable (lab supported) or definite ALS [16]. Both patient with
and without a family history for ALS or frontotemporal dementia participated in this study.
Age at onset was defined as age at appearance of first muscle weakness, difficulty speaking or
swallowing. Survival was defined as time from disease onset to death, tracheostomy or non-
invasive ventilation >23 hours a day. Survival status of patients is regularly checked through
the Dutch Municipal Personal Record Database and ALS care teams. The date of the last check
served as the censoring date in survival analyses. The controls were population-based subjects,
matched for gender and age, free of any neuromuscular disease [17]. Finally, the 75 ALS-mim-
ics were patients who were referred to our out-patient clinic for motor neuron disease in
whom ALS was suspected. After reviewing the patient’s history, neurological examination,
additional diagnostic tests and considering the course of the disease, one or more neurologists
specialized in motor neuron diseases made an alternative diagnosis (Table A in S1 File).
Patients with primary lateral sclerosis and progressive muscular atrophy were excluded. All
participants gave written informed consent and the Medical Ethics Committee at the Univer-
sity Medical Center Utrecht approved this study.
RNA isolation and quality control
In the patient group, blood was drawn in the morning on the day they were seen at our clinic
because of suspected ALS or within 60 days after the initial visit. Control subjects’ blood was
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also obtained in the morning. Venous blood was collected in PAXgene tubes containing
reagents that immediately stabilize messengerRNA (mRNA). After maintaining samples at
room temperature for 2 hours, tubes were stored at -20 ˚C. For isolation and purification of
mRNA, PAXgene extraction kits (Qiagen) were used according to the manufacturer’s protocol.
This included purification by DNAse treatment. Globin reduction treatments were not per-
formed. Quality of isolated RNA was assessed using the Agilent 2100 Bioanalyzer system. Sam-
ples with RNA Integrity Number (RIN) values< 7 were dismissed. Furthermore, quality was
assessed by visual inspection of gel electrophoresis patterns.
Gene expression profiling
Before RNA hybridization, samples were randomized to avoid batch effects correlated to the
diagnosis. Samples were hybridized to two different platforms at two different laboratories:
Illumina’s HumanHT-12 version 3 and version 4 BeadChips according to manufacturer’s pro-
tocol (Illumina, Inc., San Diego, CA, U.S.A.).
Quality control—Data preparation
Final Reports from Illumina’s GenomeStudio were imported in R (http://cran.r-project.org).
After quantile normalization, gender was checked by expression of gender-specific Y chromo-
somal probes (JARID1D and RPS4Y1). Samples with gender mismatches were excluded. Subse-
quently expression values were log2 transformed and quantile normalized. Arrays were
projected along the first and second principal component and outliers were dismissed. This
resulted in the exclusion of 34 patients and 33 control subjects from the training set and exclu-
sion of 13 patients and 7 control subjects from the test-validation set.
High quality probes were selected, including true autosomal probes only. Using the BLAT
function in UCSC’s Genome Browser, all probes were aligned to the NCBI reference genome
build 36. Probes with multiple BLAT hits with a sequence homology of> 95% were defined as
aspecific and excluded from further analysis. We looked for retired probes using the RefSeq
and UniGene (build #228) databases. Retired probes were excluded from further analysis.
Finally, probes with identical probe IDs that overlapped between the Illumina HumanHT12 v3
and v4 platform were selected.
Surrogate variable analysis
To eliminate expression heterogeneity caused by known and unknown technical and biologi-
cal background, data from both training and test sets were combined and normalized, applying
surrogate variable analysis (SVA). This produces surrogate variables for which expression lev-
els can be corrected by calculating residuals in a linear regression model. In previous studies,
this correction has been proven to reduce batch-sp3ecific background noise, thereby increas-
ing the ability to detect biologically meaningful signals [18].
Differential expression
To find differentially expressed genes in a two-stage (discovery-replication) design, we used
the larger cohort hybridized to the IlluminaHT-12 v3 BeadChip in the discovery phase and
that hybridized to the IlluminaHT-12 v4 BeadChip in the replication phase. Because the com-
bination of p-values with the fold change to determine differential expression has proven more
robust than p-values alone, we combined both parameters to define differential expression
[19]. The p-values were calculated applying linear regression corrected for age, gender, riluzole
Gene expression as biomarker in ALS
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use and the surrogate variables. For replication purposes, genes that showed differential
expression (p< 0.05 unadjusted for multiple testing) and a 1.5-fold median change were taken
to the replication phase. In the replication phase transcripts were considered differentially
expressed when the met 2 criteria:
• An FDR corrected p-value < 0.05 from linear regression.
• A 1.5-fold change in median expression values between ALS cases and controls.
For these genes, enrichment of gene ontology processes and KEGG pathways was examined
using DAVID Bioinformatics Resources 6.7 (http://david.abcc.ncifcrf.gov) [20]. Furthermore,
we performed tissue enrichment analysis for differentially expressed genes using FUMA [21].
For both functional and tissue enrichment analysis we used all probes passing quality control
as background.
Next, we assessed whether subgroups of ALS patients exhibit distinct gene expression pat-
terns. For this purpose, we split the group of ALS patients based on site of onset (bulbar vs. spi-
nal onset) and C9orf72 status (wild-type vs. expanded) and split the control cohort into two
proportionally sized cohorts. We applied surrogate variable analysis with 3 phenotype groups:
bulbar, spinal and control for site of onset and wild-type, expanded and control for C9orf72
status. In the SVA-corrected data we compared the effect-estimates and p-values for differen-
tially expression between both subgroups (bulbar vs. spinal onset and C9orf72wild-type vs.
expanded).
Predicting disease status
We used four different methods to train models that could be used to predict disease status:
linear discriminant analysis (LDA), support vector machines (SVM) [22], nearest shrunken
centroid (NSC) [15] and least absolute shrinkage and selection operator (LASSO) [23]. These
approaches are available through the R packages MASS, e1071, pamr and glmnet respectively
(cran.r-project.org).
In a biomarker approach, the trained model is ideally validated in an external, independent
cohort. To keep the test/validation set totally independent, we eliminated batch effects by SVA
on the training and test/validation set separately. Subsequently, the models were trained on the
training set and their performance was assessed in the independent test/validation set (Fig 1a).
This approach, however, can suffer from batch effects between the training set and test/valida-
tion set that are not captured by SVA since both sets were not combined. As a consequence,
the chances of externally validating the model are limited. We therefore took a second
approach, where we combined the training and test set to remove batch effects, by applying
SVA on this dataset as a whole (Fig 1b). The training and test set were subsequently separated
again before training and testing the model. Using this approach, however, the test set can no
longer be considered an independent validation set. To approximate an independent dataset,
we used the validation set, that included samples that were not used in the SVA but were
hybridized in the same batch as the test set. These validation samples were normalized using
the surrogate variables derived from the training and test set. For SVA, labelling samples as
ALS or control subject a priori is essential for normalization. This entails the risk of overesti-
mating the prediction model’s performance and in a clinical practice this label would be
unknown. Therefore, the validation samples were normalized twice, as ALS sample and as con-
trol, regardless of their true class. The highest probability for each class, defined by the models,
was chosen as the definite class prediction. Likewise, the mimics were also included in this vali-
dation set.
Gene expression as biomarker in ALS
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Predicting survival
To predict survival in patients, a previously described modification of the nearest shrunken
centroid algorithm was used [24]. This algorithm uses the probes that were associated with
survival in a Cox proportional hazards model corrected for gender, age at onset and site of
onset (spinal versus bulbar) in the training set. Based on expression profiles of these probes,
patients in the training set were clustered into two groups: those with long survival and those
with short survival. Subsequently, the NSC prediction model was developed using the survival-
Fig 1. Procedures for training, testing and validation of the classifiers. (a) In the first approach the training and
test/validation set were treated as totally separate sets. (b) In the second approach batch effects between the training
and test set were overcome by surrogate variable analysis, after which the sets were separated and the models were
trained and tested. The samples in the validation set were corrected using the surrogate variables twice, labelled as ALS
and as control, before assessing the performance of the models.
https://doi.org/10.1371/journal.pone.0198874.g001
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associated probes in these two groups after which this model classified samples in the test set
as long or short survivor. We assessed the performance of this prediction model by testing the
association between the predicted survival class (long vs. short) and true survival in a Cox pro-
portional hazards model.
Results
Study population
Baseline characteristics for the 397 ALS patients, 645 control subjects and 75 ALS-mimics that
passed quality control were virtually identical between the different sets (Table 1). Patients
with diseases mimicking ALS were more frequently male and were younger than ALS patients
and controls. The spectrum of diagnoses in the ALS-mimics reflected the clinical practice of
our tertiary referral center for motor neuron diseases (Table A in S1 File).
Data preparation
In total, 29,830 unique, autosomal, non-retired probes were present on both the Illumina
HumanHT-12 v3 and v4 BeadChip and were suitable for further analysis. Correction for
expression heterogeneity, reflecting the technical and biological background (especially batch
effects) by surrogate variable analysis (SVA) of our training and test set, resulted in 34 surro-
gate variables. Fig 2 displays the elimination of batch effects that dominated expression profiles
before SVA correction.
Differential expression analysis reveals pathways involved in ALS
pathogenesis
Linear regression identified 7,038 genes that were expressed differentially between patients
and control subjects in the discovery set. Of these genes, 2,943 were expressed differentially
in the replication set (FDR corrected p-value < 0.05) with at least a 1.5-fold change between
patients and control subjects. Gene Ontology (GO) analysis of molecular functions identified
RNA binding (P = 8.61 × 10−9, FDR corrected P = 1.43 × 10−5) and enzyme binding (P =
1.20 × 10−5, FDR corrected p = 1.99 × 10−2) as the most enriched molecular functions; other
molecular functions were not significantly enriched after FDR correction for multiple testing
(Table 2). The biological process, intracellular transport (P = 4.01 × 10−8, FDR corrected
Table 1. Baseline characteristics.
Training set Test set Validation set
ALS Controls ALS Controls ALS Controls Mimics
N 233 508 114 87 50 50 75
Gender (% female) 38.6 44.7 41.2 44.8 42 38 23
C9orf72 (%) 5.2 - 14.9 - 8.0 - -
Age (IQR) 64.7 (57–72) 62.9 (57–69) 61.1 (55–68) 62.4 (57–69) 64.5 (55–69) 60.0 (55–65) 57.9 (47–64)
Age at onset (IQR) 63.9 (56–71) 61.8 (55–71) 64.9 (55–70)
Survival (IQR) 31.3 (21–36) 27.0 (18–40) 30.5 (24–40)
Bulbar (%) 38.6 39.5 22.0
Platform HT-12 V3 HT-12 V4 HT-12 V4
C9orf72 was not tested in controls or ALS mimics. Median follow-up for survival was 4.4 years (min 1.8 years, max 9.7 years).
 p = 0.004, χ2-test comparing training and test set.
IQR = interquartile range, HT-12 = Illumina HumanHT-12 expression array
https://doi.org/10.1371/journal.pone.0198874.t001
Gene expression as biomarker in ALS
PLOS ONE | https://doi.org/10.1371/journal.pone.0198874 June 25, 2018 6 / 14
P = 7.47 × 10−5), was most significantly enriched after correction for multiple testing. Fur-
thermore, the GO biological process programmed cell death was significantly enriched for
genes differentially expressed between ALS patients and healthy controls (P = 7.53 × 10−7,
FDR corrected P = 1.40 × 10−3). Other enriched processes were closely related to either intra-
cellular transport or programmed cell death (Table 2). Finally, KEGG (Kyoto Encyclopedia
of Genes and Genomes) enrichment analysis did not identify any significantly enriched path-
ways after FDR correction. We found the differentially expressed genes most highly
expressed in blood and spleen tissue compared to the other 30 general tissues studied in
GTEx (Fig A in S1 File). This might reflect the increase in power to detect differentially
Fig 2. Elimination of expression heterogeneity by surrogate variable analysis. The left heatmap displays the
expression of the 5,000 most variable probes before correction by surrogate variable analysis. The right heatmap
displays the expression of the 5,000 probes after correction by surrogate variable analysis. Rows display arrays and
columns reflect probes. Arrays are clustered by hierarchical clustering. Black lines reflect patients and grey lines
control subject. Red lines display array hybridized on Illumina’s HumanHT-12 version 3 BeadChips and blue lines
those hybridized on version 4. Before SVA correction, arrays are perfectly clustered based on the platform used: after
SVA correction, these batch effects are corrected for.
https://doi.org/10.1371/journal.pone.0198874.g002
Table 2. Pathway analysis.
Gene Ontology—Molecular Function
Term p-value Fold Enrichment FDR N
RNA binding 8.61 × 10−9 1.57 1.43 × 10−5 150
Enzyme binding 1.20 × 10−5 1.51 0.02 105
Gene Ontology—Biological Processes
Term p-value Fold Enrichment FDR N
Intracellular transport 4.01 × 10−8 1.56 7.47 × 10−5 140
Protein transport 5.60 × 10−8 1.51 1.04 × 10−4 157
Establishment of protein localization 6.12 × 10−8 1.50 1.14 × 10−4 158
Programmed cell death 7.53 × 10−7 1.52 1.40 × 10−3 127
Protein localization 2.28 × 10−6 1.40 4.25 × 10−3 169
Apoptosis 4.76 × 10−6 1.48 8.88 × 10−3 122
Vesicle-mediated transport 6.88 × 10−6 1.49 0.01 117
Cell death 2.00 × 10−5 1.41 0.04 138
Top enriched Gene Ontology terms for differentially expressed genes. FDR: false discovery rate, N: number of differentially expressed genes per category.
https://doi.org/10.1371/journal.pone.0198874.t002
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expressed genes in our whole blood expression profiles for genes with overall higher expres-
sion levels in whole blood. A full list of differentially expressed genes is provided in S1 Table.
We next studied the sub-phenotypes of ALS by dividing our patient cohort based on site of
onset (spinal vs. bulbar) of C9orf72 status (wild-type vs. expanded). Here, we found no evi-
dence for heterogeneity in gene expression profiles between the sub-phenotypes as the changes
in gene expression compared to (independent) controls were highly correlated (Fig B in S1
File).
Through the first approach (Fig 1a) we trained the models (LDA, SVM, NSC and LASSO)
on the training set in which they were able to discriminate between cases and controls. Never-
theless, none of the models could discriminate between cases and controls in the test/valida-
tion set, due to severe batch effects between the training and test/validation set (Fig 3a).
Therefore, the first approach that treated the test/validation set as a totally independent dataset
did not yield a reliable biomarker.
To overcome the batch effects between the training and test/validation set we took
approach 2 that applied SVA on the training and test set combined, prior to training the mod-
els (Fig 1b). Except for LDA, this approach improved discrimination between ALS cases and
controls in the test set (Fig 3b). Shrinking of effect estimates left 106 and 77 informative genes
for NSC and LASSO respectively. All models, except LDA, were taken to the validation phase
where they were tested to predict the class of 50 ALS cases and 50 controls. Whereas all classifi-
ers performed well in the validation phase, the resulting receiver operator curves indicated the
LASSO model performed best (area under curve = 0.90, Fig 4a). We next assessed whether the
label used for SVA (ALS or control) in the validation set could have resulted in biased predic-
tions. Overall the probabilities were highly correlated with some evidence for bias in the SVM
and NSC classifiers (R2 = 0.89 for both), but not for LASSO (R2 = 0.97, Fig C in S1 File). In
contrast to the high accuracy obtained when discriminating ALS patients from healthy con-
trols, none of the models performed well when they were tested in the set of 50 ALS cases and
75 ALS-mimics (area under curve 0.65–0.68, Fig 4b).
Fig 3. Probabilities for training and test/validation set. Boxplots of probabilities given by the four different models (LDA, SVM, NSC and LASSO) in the training
and test/validation set for approach 1 (a) and approach 2 (b).
https://doi.org/10.1371/journal.pone.0198874.g003
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Gene expression profiles do not serve as a biomarker for survival
In the training set, expression of 2,324 genes was significantly associated with survival in a Cox
proportional hazards model corrected for gender, age at onset and site of onset. We then
trained a survival prediction model applying the NSC algorithm including the probes associ-
ated with survival in the training set. The prediction model divided patients in the training set
into two groups: those with long and those with short survival (cut-off = 2.34 years, Fig 5a). In
the test set, the actual survival time for the predicted long survivors was, however, virtually
similar to the survival time in the predicted short survivors (median = 2.82 and 2.28 years
respectively, p = 0.35, Fig 5b). This means the expression of any subset of these 2,324 genes
was not sufficiently informative to predict survival for ALS patients.
Fig 4. Receiver operator curves for validation set. (a) Receiver operator curves for the SVM, NSC and LASSO
classifiers in the validation set when discriminating between ALS cases from controls and (b) discriminating ALS cases
from ALS-mimics.
https://doi.org/10.1371/journal.pone.0198874.g004
Fig 5. Survival curves for predicted survival classes. (a) Differences in survival time for the so-termed “long
survivors” and “short survivors” in the training set, which was used as input to train the nearest shrunken centroid
survival model. (b) The differences in true survival between the predicted “long survivors” and predicted “short
survivors” in the test set.
https://doi.org/10.1371/journal.pone.0198874.g005
Gene expression as biomarker in ALS
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Discussion
Using transcriptome-wide analyses, assessing differential expression, we have shown that
whole blood mRNA profiles were able to detect pathways involved in motor neuron patho-
physiology in ALS patients. We found 2,943 genes to be differentially expressed, which were
predominantly involved in RNA processing and cellular transport, which are key pathways in
ALS pathogenesis [6]. In an effort to find a clinically useful diagnostic biomarker, we applied
four different algorithms in two different approaches including ALS patients, healthy controls
and ALS-mimics. After correction for severe batch effects, the models could discriminate well
between ALS patients and healthy controls. We subsequently assessed its performance includ-
ing ALS-mimics to represent a tertiary referral clinical setting, a crucial step that is often omit-
ted in biomarker research. Unfortunately, the models failed to distinguish between ALS
patients and ALS-mimics, nor could we predict survival.
RNA processing is one of the best-established pathways involved in ALS pathogenesis.
Common causes of familial ALS, including TARDBP and FUS mutations, as well as polygluta-
mine repeat expansions in ATXN2 and SMN1 duplications as susceptibility factors for sporadic
ALS, all play an important role in multiple aspects of RNA processing [25–28]. Furthermore,
RNA foci are observed in cells harboring the C9orf72 repeat expansion. It has been hypothe-
sized that this leads to RNA-mediated toxicity caused by sequestering of RNA binding proteins
in these foci [29,30]. Alternatively, RAN translation of this repeat can lead to nucleolar
stress and neurodegeneration via the suppression of ribosomal RNA synthesis [31]. We did
not find any of the known ALS-associated genes involved in RNA binding to be differentially
expressed. Nevertheless, we did find TARBP2 and HNRNPA(0/B), genes closely related to
TARDBP and FUS respectively, to be differentially expressed. Other differentially expressed
gene families involved in RNA processing were ribosomal proteins (RPL4, RPL5, RPL8, RPL15,
RPL19, RPL22, RPLP0, RPLP1, RPLP2, RPS13, RPS15A,RPS25, RPUSD4), DEAD-box proteins
(DDX17, DDX19A, DDX19B, DDX21, DDX24, DDX31, DDX50, DDX51) and eukariotic trans-
lation initiation factors (EIF2A, EIF2C1, EIF3B, EIF4A2, EIF4A3, EIF5A). Interestingly, a recent
study showed that, although gene expressions profiles can be highly tissue-spedific [32], many
genes involved in RNA processing were differentially expressed in fibroblasts [33]. This,
together with our observations, suggests that gene expression profiles in non-neuronal tissue
can reflect motor neuron pathology in ALS patients. The identification of RNA processing
using an unbiased approach underlines its importance in ALS pathogenesis, and the potential
for whole blood gene expression profiles to highlight motor neuron pathology.
Apart from RNA processing, we found genes involved in intracellular transport to be differ-
entially expressed. As motor neurons are highly polarized, intracellular transport—and specifi-
cally axonal transport—is crucial to maintain their function. In SOD1G93A transgenic mice,
impaired axonal transport precedes symptomatic muscle weakness suggesting this might be an
early feature of ALS pathology [34]. Furthermore, VAPB mutations have been shown to impair
axonal transport of mitochondria, a finding also observed in SOD1G93A transgenic mice [35].
Finally, ALS-specific mutations in TARDBP impair anterograde axonal transport of mRNA in
drosophila and mouse models [36]. These observations corroborate the premise that cellular
transport plays a crucial role in ALS pathogenesis.
We have shown batch effects between hybridization platforms and laboratories severely
challenge the development of a reliable biomarker that uses gene-expression microarrays.
When both our datasets were combined, however, and batch effects were corrected for, three
different models were able to differentiate accurately between patients and healthy controls.
We note that the performance of our prediction models was not affected by the difference in
C9orf72 carriers between the training and testing set. This indicates that whole blood gene
Gene expression as biomarker in ALS
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expression profiles harbour information that might ultimately be used as a diagnostic bio-
marker. Although this seems promising, important challenges need to be overcome.
First, the models should be robust to batch effects so they can be externally validated. We
did not achieve this in our original approach and it is therefore possible that the models we
have developed in our second approach will not perform well in an external dataset. The batch
effects, however, are almost inherent to the technique used for microarray hybridization [37].
Therefore, alternative techniques such as RNAseq can be used. Whereas RNAseq also suffers
from batch effects, many strategies have been developed to correct for these batch effects inter-
nally (normalization within a batch), which may ultimately yield better normalized signals
than those obtained through microarrays [38]. Considering that gene expression profiles can
tissue-specific32, another strategy is to obtain a better signal to noise ratio, is to study the pri-
marily affect tissue. The ability to study primarily affected tissue has been responsible for the
success of microarray-based gene expression biomarkers in the cancer field [14,39,40]. To
obtain neuronal tissue from ALS patients and controls, however, will limit the sample size for
biomarker discovery and raises ethical questions when applied in a clinical diagnostic setting.
The second challenge that needs to be overcome before a biomarker can be applied in the
clinic, is that it should be able to discriminate between ALS patients and ALS-mimics. This
crucial step is often omitted in biomarker studies. Whereas our models performed well when
in a case-control setting, they did not discriminate well between ALS cases and mimics. One
possible explanation is that some ALS-mimics not only resemble ALS clinically, but also
exhibit a similar gene expression profile. This could be caused by shared pathways in disease
etiology, as is seen among neurodegenerative diseases [41]. Alternatively, gene expression pro-
files of ALS patients may partly reflect secondary mechanisms caused by acquired muscle
weakness, also present in ALS-mimics. Future studies should therefore include an even larger
number of ALS-mimics, so even more subtle gene expression changes between ALS patients
and ALS-mimics can be picked up when training the models.
Finally, changes in whole blood-derived gene expression profiles are easily obtained and, as
we have shown, in part reflect motor neuron biology in ALS. Alternative ways to follow up
these observations, include studying longitudinal gene expression measurements in ALS
patients. These profiles, easily collected in clinical trials, can shed light on changes in perturbed
biological processes during the disease course. Furthermore, developing an easily obtained
biomarker, that can monitor disease progression is highly warranted for effective trial design.
In conclusion, we have shown that whole blood transcriptome profiles are able to reveal
biological processes involved in ALS. Also, this study shows that using these profiles to differ-
entiate between ALS and mimic syndromes will be challenging, even when taking batch effects
in transcriptome data into account.
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